Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV plus diffuse large B-cell lymphoma patient

被引：3

作者：

Wang, Jing ^{[1
]}

Zhang, Renfang ^{[1
]}

Ding, Xiangqing ^{[1
]}

Jin, Yanling ^{[1
]}

Qin, Ran ^{[1
]}

Xia, Bili ^{[1
]}

Liao, Qibin ^{[1
]}

Hu, Huiliang ^{[1
]}

Song, Wei ^{[1
]}

Wang, Zhenyan ^{[1
]}

Zhang, Xiaoyan ^{[2
,3
]}

Xu, Jianqing ^{[2
,3
]}

机构：

[1] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China

[2] Fudan Univ, Zhongshan Hosp, Shanghai 201508, Peoples R China

[3] Fudan Univ, Inst Biomed Sci, Shanghai 201508, Peoples R China

来源：

IMMUNOTHERAPY | 2022年 / 14卷 / 08期

基金：

国家重点研发计划;

关键词：

anti-CD20; antibody; chemo-immunotherapy; DLBCL; HIV plus; iNKT; pathologically complete regression; relapsed; refractory; rituximab; THERAPY; RITUXIMAB; RESPONSES; CULTURE; CHOP;

D O I：

10.2217/imt-2021-0247

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Although there is a high curability rate with rituximab chemotherapy, approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) develop disease relapse or primary-refractory lymphoma. The prognosis of HIV+ DLBCL patients is even worse with limited therapeutic options. The case is presented of a 28-year-old man who was diagnosed with HIV-DLBCL, refractory to rituximab-based chemo-immunotherapies and radiotherapy before and maintained a pathologically complete regression with the infusion of haplotype-matched invariant NK T cells and anti-CD20 antibody. His abdominal mass kept shrinking during the period of follow-up without relapse to date. A combination of haplotype-matched invariant NK T cells was likely to reinvigorate the efficacy of anti-CD20 antibody and may offer a viable treatment option for refractory DLBCL patients. Plain language summary Diffuse large B-cell lymphoma (DLBCL) is one of the most frequent types of lymphoid cancer. The prognosis of relapsed/refractory DLBCL patients has been dismal with resistance to rituximab-based chemo-immunotherapy. The combination of effective cells with rituximab might improve clinical response by enhancing antibody-dependent cytotoxicity. The authors reported the case of a 28-year-old man diagnosed with HIV-DLBCL, refractory to 3 lines of rituximab-based chemo-immunotherapies and radiotherapy before, and who received 6 experimental infusions of haplotype-matched invariant NK T cells combined with anti-CD20 antibody. The lesion on radiological examination was partially regressed after cycle 3 and cycle 6. The pathological examination, performed 4 weeks after cycle 6, suggested pathologically complete regression. The mass was completely regressed on CT scanning without relapse to date. A combination of invariant NK T cells and anti-CD20 antibody may offer a viable treatment option for relapsed/refractory DLBCL patients for whom rituximab chemotherapy was not effective.

引用

页码：599 / 607

页数：9

共 27 条

[1] Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis [J].

Abbasi, Ahmed ;

Peeke, Stephen ;

Shah, Nishi ;

Mustafa, Jennat ;

Khatun, Fariha ;

Lombardo, Amanda ;

Abreu, Michelly ;

Elkind, Richard ;

Fehn, Karen ;

de Castro, Alyssa ;

Wang, Yanhua ;

Derman, Olga ;

Nelson, Randin ;

Uehlinger, Joan ;

Gritsman, Kira ;

Sica, R. Alejandro ;

Kornblum, Noah ;

Mantzaris, Ioannis ;

Shastri, Aditi ;

Janakiram, Murali ;

Goldfinger, Mendel ;

Verma, Amit ;

Braunschweig, Ira ;

Bachier-Rodriguez, Lizamarie .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)

[2] Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma [J].

Abramson, Jeremy S. ;

Irwin, Kelly E. ;

Frigault, Matthew J. ;

Dietrich, Jorg ;

McGree, Brianne ;

Jordan, Justin T. ;

Yee, Andrew J. ;

Chen, Yi-Bin ;

Raje, Noopur S. ;

Barnes, Jeffrey A. ;

Davis, Benjamin .

CANCER, 2019, 125 (21) :3692-3698

[3] NK cell function in HIV-1 infection [J].

Alter, Galit ;

Altfeld, Marcus .

CURRENT MOLECULAR MEDICINE, 2006, 6 (06) :621-629

[4] HIV-associated lymphomas and gamma-herpesviruses [J].

Carbone, Antonino ;

Cesarman, Ethel ;

Spina, Michele ;

Gloghini, Annunziata ;

Schulz, Thomas F. .

BLOOD, 2009, 113 (06) :1213-1224

[5] Immunotherapy and the Role of Imaging [J].

Carter, Brett W. ;

Bhosale, Priya R. ;

Yang, Wei T. .

CANCER, 2018, 124 (14) :2906-2922

[6] Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect [J].

DiLillo, David J. ;

Ravetch, Jeffrey V. .

CELL, 2015, 161 (05) :1035-1045

[7] Causes of death in HIV-infected patients from the Cologne-Bonn cohort [J].

Ehren, K. ;

Hertenstein, C. ;

Kuemmerle, T. ;

Vehreschild, J. J. ;

Fischer, J. ;

Gillor, D. ;

Wyen, C. ;

Lehmann, C. ;

Cornely, O. A. ;

Jung, N. ;

Gravemann, S. ;

Platten, M. ;

Wasmuth, J. C. ;

Rockstroh, J. K. ;

Boesecke, C. ;

Schwarze-Zander, C. ;

Faetkenheuer, G. .

INFECTION, 2014, 42 (01) :135-140

[8] Antibody-dependent CD56+T cell responses are functionally impaired in long-term HIV-1 infection [J].

Fan, Xueying ;

Zhu, Liyan ;

Liang, Hua ;

Xie, Zhe ;

Huang, Xiangbo ;

Wang, Shuo ;

Shen, Tao .

RETROVIROLOGY, 2016, 13

[9] Mechanisms of killing by anti-CD20 monoclonal antibodies [J].

Glennie, Martin J. ;

French, Ruth R. ;

Cragg, Mark S. ;

Taylor, Ronald P. .

MOLECULAR IMMUNOLOGY, 2007, 44 (16) :3823-3837

[10] Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma [J].

Habermann, Thomas M. ;

Weller, Edie A. ;

Morrison, Vicki A. ;

Gascoyne, Randy D. ;

Cassileth, Peter A. ;

Cohn, Jeffrey B. ;

Dakhil, Shaker R. ;

Woda, Bruce ;

Fisher, Richard I. ;

Peterson, Bruce A. ;

Horning, Sandra J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3121-3127

← 1 2 3 →